1️⃣ Psychedelics just got a federal fast lane
The White House signed an April 18 order directing priority vouchers for eligible breakthrough-designated psychedelic drugs, a Right to Try access path and at least $50M for state-linked research.
💡 Why it matters
It does not approve a drug. It shortens the path to one and lowers the policy discount investors usually apply to the category.
☕ Coffee talk
How many models still price this space like fringe science when Washington just put a clock on it?
2️⃣ Roche is buying MRD scale, not just another test
Roche agreed on April 16 to buy SAGA Diagnostics for up to $595M, adding Pathlight, a tumor-informed MRD platform already covered by Medicare in early-stage breast cancer.
💡 Why it matters
MRD is moving from specialist assay to monitoring stack. Roche is paying early to own a platform before recurrence testing spreads across more tumor types.
☕ Coffee talk
MRD is still supposed to be early, so why are the big platforms already shopping like the category is decided?
3️⃣ AstraZeneca now has a third pivotal COPD win
AstraZeneca said on April 20 that tozorakimab met the primary endpoint in the Phase III MIRANDA trial, reducing moderate-to-severe COPD exacerbations on top of inhaled standard care.
💡 Why it matters
A third pivotal win matters more than the first two. It makes IL-33 look closer to a filing path than another interesting mechanism.
☕ Coffee talk
Does this finally make COPD a biologics market, or do payers still treat it like an expensive inhaler add-on?